Pharmacokinetics
Cross-source consensus on Pharmacokinetics from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Benefits
Evidence quality
Highlighted claims
- Favipiravir pharmacokinetics were best described by a one-compartment model with oral absorption, absorption lag time, and linear elimination. — Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial
- Higher body weight correlated with higher favipiravir clearance. — Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial
- Favipiravir exposure was higher on day 1 than at steady state because the loading dose rapidly attained therapeutic concentrations. — Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial
- Favipiravir exposure remained above estimated effective concentrations throughout treatment. — Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial
- Favipiravir nonlinearity could not be excluded because the trial had a small sample size. — Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial